Ariceum Therapeutics

📍 Berlin, Germany🗓 Founded 2021👥 20 employees💰 Last funded 2021
Biotechnology Research🌐 ariceum-therapeutics.com
Website LinkedIn
Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Ariceum Therapeutics?
Ariceum Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Ariceum Therapeutics last raise funding?
The most recent investment in Ariceum Therapeutics recorded on gritt.io was in 2021.
When was Ariceum Therapeutics founded?
Ariceum Therapeutics was founded in 2021.
What industry is Ariceum Therapeutics in?
Ariceum Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ariceum Therapeutics based?
Ariceum Therapeutics is headquartered in Berlin, Germany.